In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin:: Six years of global surveillance
In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin:: Six years of global surveillance
复制标题
DOI:
10.1128/jcm.01901-07
复制
发表时间:
2008-01-01
影响因子:
9.4
通讯作者:
Diekema, D. J.
中科院分区:
文献类型:
--
作者:
Pfaller, M. A.;Boyken, L.;Diekema, D. J.
The echinocandins are being used increasingly as therapy for invasive candidiasis. Prospective sentinel surveillance for the emergence of in vitro resistance to the echinocandins among invasive Candida sp. isolates is indicated. We determined the in vitro activities of anidulafungin, caspofungin, and micafungin against 5,346 invasive (bloodstream or sterile-site) isolates of Candida spp. collected from over 90 medical centers worldwide from I January 2001 to 31 December 2006. We performed susceptibility testing according to the CLSI M27-A2 method and used RPMI 1640 broth, 24-h incubation, and a prominent inhibition endpoint for determination of the MICs. Of 5,346 invasive Candida sp. isolates, species distribution was 54% C. albicans, 14% C. parapsilosis, 14% C. glabrata, 12% C. tropicalis, 3% C. krusei, 1% C. guilliermondii, and 2% other Candida spp. Overall, all three echinocandins were very active against Candida: anidulafungin (MIC50, 0.06 mu g/ml; MIC90, 2 mu g/ml), caspofungin (MIC50, 0.03 mu g/ml; MIC90, 0.25 mu g/ml), micafungin (MIC50, 0.015 mu g/ml; MIC90, 2 mu g/ml). More than 99% of isolates were inhibited by